CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

To predict the CYP2C19 genotype-dependence in anti-Helicobacter pylori (H. pylori) therapy when lansoprazole or rabeprazole was used instead of omeprazole as a proton pump inhibitor (PPI). A comparative pharmacokinetic study with each PPI was designed as an open, randomized, and crossover study of 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceutical research 2001-06, Vol.18 (6), p.721-727
Hauptverfasser:	SAKAI, Toshiyuki, AOYAMA, Nobuo, KASUGA, Masato, OKUMURA, Katsuhiko, KITA, Tomoko, SAKAEDA, Toshiyuki, NISHIGUCHI, Kohshi, NISHITORA, Yukari, HOHDA, Takashi, SIRASAKA, Daisuke, TAMURA, Takao, TANIGAWARA, Yusuke
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Pyridinylmethylsulfinylbenzimidazoles Adult Aryl Hydrocarbon Hydroxylases Benzimidazoles - blood Benzimidazoles - pharmacokinetics Benzimidazoles - therapeutic use Biological and medical sciences Cross-Over Studies Cytochrome P-450 CYP2C19 Cytochrome P-450 Enzyme System - genetics Cytochrome P-450 Enzyme System - metabolism Digestive system Enzyme Inhibitors - blood Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Female Genotype Humans Lansoprazole Male Medical sciences Mixed Function Oxygenases - genetics Mixed Function Oxygenases - metabolism Omeprazole - analogs & derivatives Omeprazole - blood Omeprazole - pharmacokinetics Omeprazole - therapeutic use Pharmacology. Drug treatments Proton Pump Inhibitors Rabeprazole
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!